Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology

Juan Carlos Laguna(Hospital Clínic de Barcelona), Laura Mezquita(Hospital Clínic de Barcelona), Navneet Singh(Post Graduate Institute of Medical Education and Research), Miquel Ferriol(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Herbert H. Loong(Memorial Sloan Kettering Cancer Center), Gonzalo Recondo(Dana-Farber Cancer Institute), Joao V. Alessi(Dana-Farber Cancer Institute), Miguel García-Pardo(Hospital Universitario Ramón y Cajal), Carlos H. Barrios(Eastern Cooperative Oncology Group), Humaid O. Al‐Shamsi(Mayo Clinic in Arizona)
Therapeutic Advances in Medical Oncology
January 1, 2024
10.1177/17588359241231260
Cited by 48

Related Papers

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k